Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ Adenocarcinoma
January 24th 2020Hirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma.